Antibody-Drug Conjugates as Novel Therapeutic Agents for Non-Small Cell Lung Carcinoma with or without Alterations in Oncogenic Drivers Laura Bender SommeChristos ChouaidRoland Schott Review Article Open access 20 May 2024
Emerging Innate Immune Cells in Cancer Immunotherapy: Promises and Challenges Jennifer Wu Review Article Open access 03 May 2024
Impact of Early Access Reform on Oncology Innovation in France: Approvals, Patients, and Costs Tess MartinCatherine RioufolIsabelle Borget Original Research Article 20 April 2024 Pages: 465 - 475
CRISPR-Cas System: A New Dawn to Combat Antibiotic Resistance Muhammad Shahzad RafiqMuhammad AbuBakar ShabbirHaihong Hao Review Article 11 April 2024 Pages: 387 - 404
Next-Generation Anti-TNFα Agents: The Example of Ozoralizumab Kouhei TsumotoTsutomu Takeuchi Review Article Open access 08 April 2024 Pages: 341 - 351
Research Advances in Stem Cell Therapy for Erectile Dysfunction Wei WangYing LiuCong-hui Han Review Article Open access 23 March 2024 Pages: 353 - 367
Additional Data in Expanded Patient Populations and New Indications Support the Practice of Biosimilar-to-Biosimilar Switching Hillel P. CohenWolfram Bodenmueller Current Opinion Open access 23 March 2024 Pages: 331 - 339
Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database Paola Maria CutroneoElena ArzentonGianluca Trifirò Original Research Article Open access 15 March 2024 Pages: 425 - 448
Targeted Gene Insertion: The Cutting Edge of CRISPR Drug Development with Hemophilia as a Highlight Zhenjie ZhangSiqi ZhangBo Feng Review Article Open access 15 March 2024 Pages: 369 - 385
Use of Biosimilars: A Systematic Review of Published Position Statements and Recommendations from Health Organisations and Societies Noraisyah Mohd SaniZoriah AzizAdeeba Kamarulzaman Systematic Review 12 March 2024 Pages: 405 - 423
Can Endangered Biosimilar Markets be Rescued? The Need to Bridge Competing Interests for Long-Term Gain Teresa Barcina LacostaArnold G. VultoSteven Simoens Commentary 26 February 2024 Pages: 325 - 329
Consensus-Based Overarching Principles and Recommendations on the Use of Biosimilars in the Treatment of Inflammatory Arthritis in the Gulf Region Khalid A. AlnaqbiNasra Al AdhoubiTore K. Kvien Original Research Article Open access 25 February 2024 Pages: 449 - 463
Cardiovascular Adverse Drug Reactions of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies for Migraine Prevention: An Analysis from the European Spontaneous Adverse Event Reporting System Emanuela Elisa SorbaraMaria Antonietta BarbieriEdoardo Spina Original Research Article 25 February 2024 Pages: 275 - 285
Nano–Bio Interactions: Exploring the Biological Behavior and the Fate of Lipid-Based Gene Delivery Systems Seigo KimuraHideyoshi Harashima Review Article 12 February 2024 Pages: 259 - 273
Recombinant Antibody Fragments for Immunotherapy of Parkinson’s Disease Karen ManoutcharianGoar Gevorkian Review Article Open access 27 January 2024 Pages: 249 - 257
Reducing Immunogenicity by Design: Approaches to Minimize Immunogenicity of Monoclonal Antibodies Chantal T. HarrisSivan Cohen Review Article Open access 23 January 2024 Pages: 205 - 226
Correction to: Is the Availability of Biosimilar Adalimumab Associated with Budget Saving? A Difference-in-Difference Analysis of 14 Countries Hyunjung WooGyeongseon ShinSeungJin Bae Correction Open access 22 January 2024 Pages: 323 - 323
Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases Suxiang ChenSaumya Nishanga HeendeniyaRakesh N. Veedu Leading Article Open access 22 January 2024 Pages: 177 - 203
Could a Long-Acting Prodrug of SN-38 be Efficacious in Sacituzumab Govitecan-Resistant Tumors? Daniel V. SantiGary W. AshleyFrancois-Clement Bidard Current Opinion Open access 18 January 2024 Pages: 171 - 176
Unveiling the Biosimilar Paradox of Oncologists’ Perceptions and Hesitations in South Korea: A Web-Based Survey Study Gyeongseon ShinByung Soo KimSeungJin Bae Original Research Article Open access 12 January 2024 Pages: 301 - 311
Safety, Tolerability, and Preliminary Efficacy of Serplulimab, a Novel Anti-PD-1 Antibody, in Patients with Metastatic or Recurrent Solid Tumors: A Phase I Study Ching-Liang HoTsu-Yi ChaoHsuan-Yu Lin Original Research Article 09 January 2024 Pages: 287 - 299
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Anti-IFNAR1 Monoclonal Antibody QX006N: A First-in-Human Single Ascending Dose Study in Healthy Chinese Volunteers Xiaojiao LiBing LiYanhua Ding Original Research Article 27 December 2023 Pages: 313 - 321
Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries Hyunjung WooGyeongseon ShinSeungJin Bae Original Research Article Open access 08 December 2023 Pages: 133 - 144
Molecular Engineering of Interleukin-2 for Enhanced Therapeutic Activity in Autoimmune Diseases Luke M. TomasovicKathy LiuJamie B. Spangler Review Article 24 November 2023 Pages: 227 - 248
Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study Kim A. PappMark G. LebwohlWoori Ko Original Research Article Open access 22 November 2023 Pages: 121 - 131
Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What Have We Learned? Ali Berkant AvciEugen FeistGerd R. Burmester Review Article Open access 21 November 2023 Pages: 61 - 71
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease Jeffrey CummingsAmanda M. Leisgang OsseJingchun Chen Review Article Open access 13 November 2023 Pages: 5 - 22
Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review Sylwia SzwecZuzanna KapłuchaPatryk Konieczny Review Article Open access 02 November 2023 Pages: 95 - 119
AAV-Based Strategies for Treatment of Retinal and Choroidal Vascular Diseases: Advances in Age-Related Macular Degeneration and Diabetic Retinopathy Therapies Brenda F. M. CastroJason C. SteelChristopher J. Layton Review Article Open access 25 October 2023 Pages: 73 - 93
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars? Nadine Kirsch-StefanElena GuillenElena Wolff-Holz Original Research Article Open access 13 October 2023 Pages: 855 - 871
Advancing Subcutaneous Dosing Regimens for Biotherapeutics: Clinical Strategies for Expedited Market Access Beate BittnerJohannes Schmidt Review Article Open access 13 October 2023 Pages: 23 - 46
Outer Membrane Vesicle Vaccine Platforms Francesca MicoliRoberto AdamoUsman Nakakana Review Article Open access 05 October 2023 Pages: 47 - 59
Immunotherapy Guided by Immunohistochemistry PD-L1 Testing for Patients with NSCLC: A Microsimulation Model-Based Effectiveness and Cost-Effectiveness Analysis Mingjun RuiYingcheng WangZhengyang Fei Original Research Article 04 October 2023 Pages: 157 - 170
Real-World Clinical Outcomes of Bevacizumab-awwb Biosimilar versus Bevacizumab Reference Product in Patients with Metastatic Colorectal Cancer Catherine PhamFang NiuRita L. Hui Original Research Article 25 September 2023 Pages: 891 - 899
Ixekizumab for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 52-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Yu XueJiankang HuHejian Zou Original Research Article 22 September 2023 Pages: 145 - 156
Malaria Vaccines: Progress to Date Danielle I. StanisicMichael F. Good Review Article Open access 20 September 2023 Pages: 737 - 756
Enzyme Engineering Strategies for the Bioenhancement of l-Asparaginase Used as a Biopharmaceutical Javiera MirandaNicolás LefinMauricio Zamorano Review Article 12 September 2023 Pages: 793 - 811
Acute Kidney Injury from Intravitreal Anti-vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Controlled Trials Yu-Chien TsaoTing-Ying ChenEdward Chia-Cheng Lai Systematic Review 07 September 2023 Pages: 843 - 854
Patients’ Perceptions of Biosimilars: A Systematic Review Qiyou WuZhitao WangJing Sun Systematic Review 07 September 2023 Pages: 829 - 841
The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune‐Mediated Inflammatory Disease Ulf Müller-LadnerAxel DignassJanet Addison Original Research Article Open access 26 August 2023 Pages: 873 - 889
Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer Khaled SanberSamuel RosnerKristen A. Marrone Review Article 21 August 2023 Pages: 775 - 791
Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer’s Perspective Hillel P. CohenMatthew TurnerGillian R. Woollett Current Opinion Open access 05 August 2023 Pages: 583 - 593
Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies Parul BerrySahil Khanna Review Article 26 July 2023 Pages: 757 - 773
Evaluating Gene Therapy as a Potential Paradigm Shift in Treating Severe Hemophilia Courtney D. ThornburgDana H. SimmonsAnnette von Drygalski Review Article Open access 25 July 2023 Pages: 595 - 606
Unlocking the Power of Complement-Dependent Cytotoxicity: Engineering Strategies for the Development of Potent Therapeutic Antibodies for Cancer Treatments Wonju LeeSang Min LeeSang Taek Jung Review Article 24 July 2023 Pages: 637 - 648
Staying Ahead of the Game: How SARS-CoV-2 has Accelerated the Application of Machine Learning in Pandemic Management Alexander H. WilliamsChang-Guo Zhan Review Article 18 July 2023 Pages: 649 - 674
Treatment with Biologic Drugs in Pediatric Behçet’s Disease: A Comprehensive Analysis of the Published Data Ezgi Deniz BatuSeher SenerSeza Ozen Review Article 29 June 2023 Pages: 813 - 828
The Emerging Safety Profile of JAK Inhibitors in Rheumatic Diseases Jasvinder A. Singh Review Article 23 June 2023 Pages: 625 - 635
Home-Based Infusion of Alglucosidase Alfa Can Safely be Implemented in Adults with Late-Onset Pompe Disease: Lessons Learned from 18,380 Infusions Imke A. M. DittersHarmke A. van KootenHidde H. Huidekoper Original Research Article Open access 16 June 2023 Pages: 685 - 698